Indomethacin pharmacokinetics in neonates: the value of volume of distribution as a marker of permanent patent ductus arteriosus closure.
Indomethacin (INDO) pharmacokinetics were examined in 18 neonates on 19 occasions, before and after patent ductus arteriosus (PDA) closure. Patients received INDO as an initial dose of 0.25 mg/kg intravenously, and INDO serum concentrations were measured 2 and 8 h after the dose. Subsequent doses were individualized based on clinical response, toxicity, and INDO pharmacokinetics. PDA status was confirmed echocardiographically at the start and end of therapy. INDO pharmacokinetic parameters varied from dose-to-dose within the same patient, and wide interpatient variability was also observed. Pre- and post-PDA closure, only INDO volume of distribution differed significantly (p less than 0.001) with mean values of 0.36 (+/- 0.06) L/kg and 0.26 (+/- 0.08) L/kg. The reason for this occurrence remains unclear. However, a new application for pharmacokinetics as a probe of physiology is demonstrated.
Gal
P
P
Greensboro Area Health Education Center, Moses H. Cone Memorial Hospital, NC 27401.
Ransom
J L
JL
Weaver
R L
RL
Schall
S
S
Wyble
L E
LE
Carlos
R Q
RQ
Brown
Y
Y
D015415:Biomarkers; D004374:Ductus Arteriosus, Patent / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D004452:Echocardiography; D006801:Humans; D007213:Indomethacin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007231:Infant, Newborn / Q000378:metabolism*
D015415:Biomarkers; D007213:Indomethacin